B. M. Pharma & Healthcare Profile
Key Indicators
- Authorised Capital ₹ 2.55 Cr
- Paid Up Capital ₹ 2.50 Cr
- Company Age 11 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 10.84 Cr
- Revenue Growth 14.58%
- Profit Growth 9.34%
- Ebitda 206.39%
- Net Worth 16.58%
- Total Assets 4.95%
About B. M. Pharma & Healthcare
B. M. Pharma & Healthcare Private Limited (BMPHPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 25 March 2013 and has a history of 11 years and ten months. Its registered office is in Guwahati, Assam, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.55 Cr and a paid-up capital of Rs 2.50 Cr.
The company currently has active open charges totaling ₹10.84 Cr.
Sanjeev Choudhury and Anamika Choudhury serve as directors at the Company.
Company Details
-
Location
Guwahati, Assam, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51909AS2013PTC011464
-
Company No.
011464
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
25 Mar 2013
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Shillong
Industry
Who are the key members and board of directors at B. M. Pharma & Healthcare?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjeev Choudhury
|
Director | 25-Mar-2013 | Current |
|
Anamika Choudhury
|
Director | 25-Mar-2013 | Current |
Financial Performance of B. M. Pharma & Healthcare.
B. M. Pharma & Healthcare Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 14.58% increase. The company also saw a slight improvement in profitability, with a 9.34% increase in profit. The company's net worth Soared by an impressive increase of 16.58%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of B. M. Pharma & Healthcare?
In 2023, B. M. Pharma & Healthcare had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹10.84 Cr
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 10.84 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 May 2014 | State Bank Of India | ₹10.84 Cr | Open |
How Many Employees Work at B. M. Pharma & Healthcare?
B. M. Pharma & Healthcare has a workforce of 67 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of B. M. Pharma & Healthcare, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped B. M. Pharma & Healthcare's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.